A Double-Blind, Placebo-Controlled, Randomized Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2018
At a glance
- Drugs JNJ-55308942 (Primary)
- Indications Epilepsy; Inflammation; Mood disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen-Cilag
- 17 Apr 2018 Status changed from recruiting to completed.
- 09 Feb 2018 Planned End Date changed from 5 Feb 2018 to 8 Mar 2018.
- 09 Feb 2018 Planned primary completion date changed from 5 Feb 2018 to 8 Mar 2018.